SOPHiA GENETICS (NASDAQ:SOPH) Insider Philippe Menu Sells 5,000 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $5.66, for a total transaction of $28,300.00. Following the completion of the sale, the insider directly owned 223,387 shares of the company’s stock, valued at $1,264,370.42. This represents a 2.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Monday, July 13th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $28,500.00.
• On Monday, July 6th, Philippe Menu sold 7,393 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.16, for a total transaction of $38,147.88.
• On Thursday, June 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.50, for a total transaction of $27,500.00.
• On Tuesday, May 26th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.95, for a total transaction of $24,750.00.

SOPHiA GENETICS Trading Down 1.4%

SOPHiA GENETICS stock opened at $5.57 on Wednesday. SOPHiA GENETICS SA has a one year low of $2.92 and a one year high of $6.77. The company’s fifty day moving average price is $5.42 and its two-hundred day moving average price is $5.09. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90. The company has a market capitalization of $467.27 million, a price-to-earnings ratio of -10.71 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The company had revenue of $21.69 million during the quarter, compared to analyst estimates of $20.40 million. SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%. On average, analysts forecast that SOPHiA GENETICS SA will post -0.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on SOPH shares. HC Wainwright initiated coverage on SOPHiA GENETICS in a research report on Monday, July 20th. They set a “buy” rating and a $12.00 target price for the company. BTIG Research reiterated a “buy” rating and set a $8.00 price target on shares of SOPHiA GENETICS in a report on Monday, June 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $9.00.

Institutional Investors Weigh In On SOPHiA GENETICS

Several hedge funds and other institutional investors have recently made changes to their positions in the business. First Dallas Securities Inc. bought a new position in shares of SOPHiA GENETICS in the first quarter worth about $50,000. Squarepoint Ops LLC bought a new stake in SOPHiA GENETICS during the 3rd quarter valued at approximately $49,000. Perkins Capital Management Inc. bought a new stake in SOPHiA GENETICS during the 4th quarter valued at approximately $49,000. Quadrature Capital Ltd acquired a new stake in SOPHiA GENETICS in the 4th quarter valued at approximately $54,000. Finally, XTX Topco Ltd acquired a new stake in SOPHiA GENETICS in the 4th quarter valued at approximately $55,000. 31.59% of the stock is owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.